CellVax News

top of page

CellVax Therapeutics

18 de fev.

Theragent and CellVax Therapeutics Announce First Manufacturing Batch in Phase 2 Trial of FK-PC101, a Novel Personalized Cancer Immunotherapy

CellVax Therapeutics

18 de fev.

CellVax is featured in the newspaper "Folha de São Paulo", Brazil.

CellVax Therapeutics

18 de fev.

Fernando Kreutz in an interview with Jornal Da Gazeta, in Brazil

CellVax Therapeutics

18 de fev.

We discovered a new way to modify this cell

CellVax Therapeutics

18 de fev.

Prostate cancer vaccine developed in Brazil could revolutionize the treatment of the disease.

CellVax Therapeutics

18 de fev.

CellVax is a featured subject on the "Fala Brasil" program on the Brazilian TV channel Record News.

CellVax Therapeutics

18 de fev.

Brazilian vaccine against prostate cancer begins to be tested in the USA

CellVax Therapeutics

17 de fev.

TV Record News interviews Fernando Kreutz

CellVax Therapeutics

30 de jan.

If the results from 230 American patients are validated, the immunotherapy could be approved in about 18 months.

CellVax Therapeutics

31 de out. de 2024

CellVax Therapeutics Announces FDA Clearance of IND Application for FK-PC101, a Novel Personalized Cancer Immunotherapy

CellVax Therapeutics

31 de out. de 2024

CellVax Submits IND Application for Individualized Cell-based Immunotherapy FK-PC101 with Support of Theragent

CellVax Therapeutics

31 de out. de 2024

Theragent to act as partner for CellVax’s Phase II cancer therapy

Developing the next generation of personalized immunotherapy

1951 NW 7TH Ave

3rd Floor | Suite 130
Miami | FL | 33136

© 2025 CellVax Therapeutics

bottom of page